'Designer' Sedative May Provide New Alternative for Colonoscopy
Remimazolam Combines Good Sedation with Fast Onset and Recovery
Source Newsroom: Wolters Kluwer Health: Lippincott Williams & Wilkins
Newswise — San Francisco, CA. (October 28, 2013) – Developed using molecular-level techniques, the "designer" sedative drug remimazolam provides a promising new alternative for sedation in patients undergoing colonoscopy, reports a study in the November issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).
"Remimazolam has the attributes of a sedative drug, with success rates comparable with recent studies of other drugs," according to the new research, led by Dr Mark T. Worthington of Johns Hopkins Hospital, Baltimore.
Remimazolam Shows Fast Onset of Sedation and Quick Recovery
The researchers evaluated the use of remimazolam, a new benzodiazepine-type sedative drug, for sedation in patients undergoing colonoscopy. As described in a recent article in Anesthesia & Analgesia, remimazolam is an example of new anesthetic and sedative drugs being developed with the use of molecular-level techniques. Remimazolam was specifically designed to have a faster onset, more predictable effects, and shorter recovery time compared to currently available sedatives.
In the "dose-finding" study, 44 volunteers received one of three different doses of remimazolam. Across dose groups, remimazolam successfully provided an adequate level of sedation for colonoscopy in three-fourths of patients.
Remimazolam achieved adequate sedation less than one minute after drug administration. Afterwards, all subjects "rapidly recovered to fully alert"—the median recovery time was less than 10 minutes.
A few subjects did not achieve adequate sedation or had minor adverse events, such as a drop in blood pressure. There were no serious or unexpected adverse events, however.
Further experiments showed that the sedative effect of remimazolam could be rapidly reversed using flumazenil—an approved medication that blocks the benzodiazepine receptor. Patients regained full alertness within one minute after flumazenil injection.
Colonoscopy is commonly performed as a screening test for colorectal cancer. For this and other brief medical procedures, some form of sedative is needed to minimize patient discomfort and optimize performance of the procedure. The ideal sedative would have a fast onset and good quality of sedation, along with rapid recovery time.
Conventional benzodiazepines provide effective sedation but relatively long recovery times—patients may not return to their normal level of alertness and functioning for several hours after the procedure. The new study is the first to compare the effects of various doses of remimazolam as sedative for colonoscopy.
The new results show "very encouraging" success rates with remimazolam, Dr Worthington and coauthors write. With its fast onset and quick recovery time—including the ability to reverse sedation almost immediately, if needed—remimazolam could be a valuable new sedative option for use in colonoscopy and other brief medical procedures. However, the researchers note that further studies will be needed to "refine the optimal dosing regimen" before remimazolam goes into widespread clinical use.
About Anesthesia & Analgesia
Anesthesia & Analgesia was founded in 1922 and was issued bi-monthly until 1980, when it became a monthly publication. A&A is the leading journal for anesthesia clinicians and researchers and includes more than 500 articles annually in all areas related to anesthesia and analgesia, such as cardiovascular anesthesiology, patient safety, anesthetic pharmacology, and pain management. The journal is published on behalf of the IARS by Lippincott Williams & Wilkins (LWW), a division of Wolters Kluwer Health.
About the IARS
The International Anesthesia Research Society is a nonpolitical, not-for-profit medical society founded in 1922 to advance and support scientific research and education related to anesthesia, and to improve patient care through basic research. The IARS contributes nearly $1 million annually to fund anesthesia research; provides a forum for anesthesiology leaders to share information and ideas; maintains a worldwide membership of more than 15,000 physicians, physician residents, and others with doctoral degrees, as well as health professionals in anesthesia related practice; sponsors the SmartTots initiative in partnership with the FDA; and publishes the monthly journal Anesthesia & Analgesia in print and online.
About Wolters Kluwer Health
Wolters Kluwer Health is a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Serving more than 150 countries and territories worldwide, Wolters Kluwer Health’s customers include professionals, institutions and students in medicine, nursing, allied health and pharmacy. Major brands include Health Language®, Lexicomp®, Lippincott Williams & Wilkins, Medicom®, Medknow, Ovid®, Pharmacy OneSource®, ProVation® Medical and UpToDate®.
Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company. Wolters Kluwer had 2012 annual revenues of €3.6 billion ($4.6 billion), employs approximately 19,000 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Follow our official Twitter handle: @WKHealth.